NCT02313610 is a Phase 2 clinical trial of Qinbudan in Pulmonary Tuberculosis, sponsored by Shanghai University of Traditional Chinese Medicine.

Who is sponsoring NCT02313610?

NCT02313610 is sponsored by Shanghai University of Traditional Chinese Medicine.

What drugs are being tested in NCT02313610?

Interventions in NCT02313610: Qinbudan, Qinbudan Placebo.

What condition does NCT02313610 study?

NCT02313610 studies Pulmonary Tuberculosis.

Is NCT02313610 still recruiting?

NCT02313610 is currently completed. Last updated 14 October 2016.

Last reviewed 2016-10-14 · How we verify

NCT02313610

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Qinbudan as an Adjunct Therapy in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Trial

Completed Phase 2 Last updated 14 October 2016

What this trial tests

Phase 2 trial testing Qinbudan in Pulmonary Tuberculosis in 253 participants. Completed in 1 March 2013.

Timeline

1 April 2011

Primary endpoint
1 March 2013

1 March 2013

Quick facts

Lead sponsor	Shanghai University of Traditional Chinese Medicine
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	253
Start date	1 April 2011
Primary completion	1 March 2013
Estimated completion	1 March 2013
Sites	12 locations across China

Drugs / interventions tested

Qinbudan — full drug profile →
Qinbudan Placebo

Conditions studied

Pulmonary Tuberculosis — all drugs for Pulmonary Tuberculosis →

Sponsor

Shanghai University of Traditional Chinese Medicine

Who can join

Adults 18 to 65, any sex, with Pulmonary Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The time of sputum conversion between the 2 groups will be evaluated
Time frame: Measured during the 8 months treatment period

Sponsor's own description

The purpose of this study is to assess the efficacy and safety of Chinese medicine Qinbudan in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
Zhang SY, Fu JY, Guo XY, Wu DZ, et al · · 2020 · cited 12× · PMID 32381098 · DOI 10.1186/s40249-020-00660-z

Verify or expand the search:

Other recruiting trials for Pulmonary Tuberculosis

Currently open trials in the same condition.

NCT07209761 — A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis · Phase 3 · recruiting
NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
NCT07186478 — I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis · NA · active not recruiting
NCT06649721 — Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort · Phase 3 · active not recruiting
NCT06528418 — Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · recruiting

Other Shanghai University of Traditional Chinese Medicine trials

Trials by the same sponsor.

NCT07331740 — Development and Application of a Parenting Anxiety Intervention Program for Young and Middle-Aged Female Breast Cancer P · NA · not yet recruiting
NCT07069049 — Electroacupuncture in the Treatment of Patients Undergoing Transperineal Prostate Biopsy Under Local Anesthesia · NA · not yet recruiting
NCT07245342 — Electroacupuncture for Improving Urinary Incontinence After Radical Prostatectomy · NA · not yet recruiting
NCT06921512 — TCM Daoyin for Anxiety/Depression: Psychological Effects and Biological Mechanisms · NA · recruiting
NCT06690606 — EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02313610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai University of Traditional Chinese Medicine
Last refreshed: 14 October 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02313610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing